EA201201374A1 - Лечение атаксии-телеангиэктазии - Google Patents
Лечение атаксии-телеангиэктазииInfo
- Publication number
- EA201201374A1 EA201201374A1 EA201201374A EA201201374A EA201201374A1 EA 201201374 A1 EA201201374 A1 EA 201201374A1 EA 201201374 A EA201201374 A EA 201201374A EA 201201374 A EA201201374 A EA 201201374A EA 201201374 A1 EA201201374 A1 EA 201201374A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- teleaggystatics
- ataxics
- treatment
- telangiectasia
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
Abstract
Изобретение относится к способам лечения атаксии-телеангиэктазии или заболевания, подобного атаксии-телеангиэктазии, соединениями, такими как токотриенолхиноны и токотриенолгидрохиноны, включая альфа-токотриенолхинон, чтобы облегчить симптомы заболевания.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34190810P | 2010-04-06 | 2010-04-06 | |
PCT/US2011/031133 WO2011126998A1 (en) | 2010-04-06 | 2011-04-04 | Treatment of ataxia telangiectasia |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201201374A1 true EA201201374A1 (ru) | 2013-04-30 |
Family
ID=44763239
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201201374A EA201201374A1 (ru) | 2010-04-06 | 2011-04-04 | Лечение атаксии-телеангиэктазии |
Country Status (8)
Country | Link |
---|---|
US (1) | US20130116336A1 (ru) |
EP (1) | EP2555765A4 (ru) |
JP (1) | JP2013523816A (ru) |
AU (1) | AU2011238525A1 (ru) |
BR (1) | BR112012025558A2 (ru) |
CA (1) | CA2795726A1 (ru) |
EA (1) | EA201201374A1 (ru) |
WO (1) | WO2011126998A1 (ru) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7470798B2 (en) | 2003-09-19 | 2008-12-30 | Edison Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
DK1888059T3 (en) * | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ, インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
ES2564179T3 (es) | 2007-11-06 | 2016-03-18 | Edison Pharmaceuticals, Inc. | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales |
US8952071B2 (en) * | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
US8716527B2 (en) | 2008-03-05 | 2014-05-06 | Edison Pharmaceuticals, Inc. | 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases |
JP5798481B2 (ja) | 2008-06-25 | 2015-10-21 | エジソン ファーマシューティカルズ, インコーポレイテッド | 酸化ストレス疾患を治療するための2−ヘテロシクリルアミノアルキル−(p−キノン)誘導体 |
WO2010030607A1 (en) | 2008-09-10 | 2010-03-18 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
CA2740773A1 (en) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells |
EP3450431B1 (en) | 2008-10-28 | 2023-09-13 | PTC Therapeutics, Inc. | Process for the production of alpha-tocotrienol and derivatives |
MX336800B (es) | 2009-04-28 | 2016-02-02 | Edison Pharmaceuticals Inc | Tratamiento de neuropatia optica hereditaria de leber y atrofia optica dominante con tocotrienol quinonas. |
DK2470168T3 (en) * | 2009-08-26 | 2018-05-07 | Bioelectron Tech Corp | PROCEDURES FOR PREVENTION AND TREATMENT OF CEREBRAL ISCAM |
CA2797581A1 (en) * | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
US9162957B2 (en) | 2011-07-19 | 2015-10-20 | Edison Pharmaceuticals, Inc. | Methods for oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols |
PE20151518A1 (es) * | 2012-11-13 | 2015-11-25 | Gordagen Pharmaceuticals Pty Ltd | Administracion transmucosa de tocotrienol |
US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
JP6810692B2 (ja) | 2014-12-16 | 2021-01-06 | ピーティーシー セラピューティクス, インコーポレイテッド | (r)−2−ヒドロキシ−2−メチル−4−(2,4,5−トリメチル−3,6−ジオキソシクロヘキサ−1,4−ジエニル)ブタンアミドの多形性形態および非晶質形態 |
US10745371B2 (en) | 2015-12-16 | 2020-08-18 | Ptc Therapeutics, Inc. | Methods for enriching alpha-tocotrienol from mixed tocol compositions |
EP3389646A1 (en) | 2015-12-17 | 2018-10-24 | BioElectron Technology Corporation | Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders |
JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | 2−置換アミノ−ナフト[1,2−d]イミダゾール−5−オン化合物またはその製薬学上許容される塩 |
JP2022505257A (ja) | 2018-10-17 | 2022-01-14 | ピーティーシー セラピューティクス, インコーポレイテッド | α-シヌクレイノパチー、タウオパチー、および他の障害を抑制および処置するための2,3,5-トリメチル-6-ノニルシクロヘキサ-2,5-ジエン-1,4-ジオン |
CA3225266A1 (en) | 2021-07-08 | 2023-01-12 | Swathi PINNAMANENI | Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7470798B2 (en) * | 2003-09-19 | 2008-12-30 | Edison Pharmaceuticals, Inc. | 7,8-bicycloalkyl-chroman derivatives |
EP1814394A4 (en) * | 2004-11-09 | 2009-08-19 | Hills Pet Nutrition Inc | USE OF ANTIOXIDANTS FOR GENE MODULATION |
DK1888059T3 (en) * | 2005-06-01 | 2015-03-30 | Edison Pharmaceuticals Inc | Redox-active therapeutic products for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
EP2262519A4 (en) * | 2008-03-05 | 2011-03-23 | Edison Pharmaceuticals Inc | TREATMENT OF HEARING AND BALANCE DEFICIENCIES WITH THERAPEUTIC AGENTS WITH REDOX ACTIVITY |
WO2010030607A1 (en) * | 2008-09-10 | 2010-03-18 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
EP2424494A1 (en) * | 2009-04-28 | 2012-03-07 | Edison Pharmaceuticals, Inc. | Formulation of tocotrienol quinones for the treatment of ophthalmic diseases |
EA201200977A1 (ru) * | 2009-12-31 | 2013-01-30 | Эдисон Фармасьютикалз, Инк. | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами |
CA2797581A1 (en) * | 2010-04-27 | 2011-11-03 | Edison Pharmaceuticals, Inc. | Formulations of quinones for the treatment of ophthalmic diseases |
-
2011
- 2011-04-04 EA EA201201374A patent/EA201201374A1/ru unknown
- 2011-04-04 BR BR112012025558A patent/BR112012025558A2/pt not_active IP Right Cessation
- 2011-04-04 CA CA2795726A patent/CA2795726A1/en not_active Abandoned
- 2011-04-04 US US13/639,494 patent/US20130116336A1/en not_active Abandoned
- 2011-04-04 WO PCT/US2011/031133 patent/WO2011126998A1/en active Application Filing
- 2011-04-04 JP JP2013503818A patent/JP2013523816A/ja not_active Ceased
- 2011-04-04 AU AU2011238525A patent/AU2011238525A1/en not_active Abandoned
- 2011-04-04 EP EP20110766566 patent/EP2555765A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2795726A1 (en) | 2011-10-13 |
BR112012025558A2 (pt) | 2016-06-28 |
EP2555765A4 (en) | 2013-08-14 |
WO2011126998A1 (en) | 2011-10-13 |
EP2555765A1 (en) | 2013-02-13 |
JP2013523816A (ja) | 2013-06-17 |
AU2011238525A1 (en) | 2012-11-08 |
US20130116336A1 (en) | 2013-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201201374A1 (ru) | Лечение атаксии-телеангиэктазии | |
EA201200977A1 (ru) | Лечение синдрома ли и ли-подобного синдрома токотриенолхинонами | |
EA201891833A1 (ru) | Комбинация для лечения амиотрофического бокового склероза или родственных болезней | |
EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201491151A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201290919A1 (ru) | Индазольные соединения и их применение | |
EA201390274A1 (ru) | Борсодержащие малые молекулы | |
EA201690007A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
EA201691354A1 (ru) | Терапевтические ингибирующие соединения | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
EA201201648A1 (ru) | Стимуляторы sgc | |
EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
EA201490030A1 (ru) | Соединения, ингибирующие металлоферменты | |
EA201591122A1 (ru) | Гетероциклическое соединение | |
EA201792465A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
EA201270257A1 (ru) | Производные n1-сульфонил-5-фторпиримидинона | |
EA201491541A1 (ru) | АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ | |
EA201170349A1 (ru) | Модуляторы mif | |
EA201101477A1 (ru) | Органические соединения и их применение | |
EA201100505A1 (ru) | Органические соединения для применения для лечения бактериальных инфекций | |
EA201300388A1 (ru) | Соединения замещенного бензамида | |
UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
EA201792471A1 (ru) | Бигетероарильные соединения и их применения |